NEW YORK, Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Related Questions
What is the potential magnitude and timeline of any stock price decline due to the lawsuit?
How might this legal exposure affect Unicycive's cash flow, financing options, and upcoming product milestones?
Are there precedent cases in the biotech sector that resulted in similar settlements or dismissals, and how did those outcomes influence comparable stocks?